Related Experiment Video
Updated: Jun 10, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Atherogenic dyslipidemia--a medical underwriter's iceberg
1drbobgleeson@msn.com
Abstract:
Life insurance medical underwriters assess cardiovascular risk by applying versions of cholesterol guidelines that were written in the early 1980s, when people were not obese, triglyceride levels were lower, and the low-density lipoprotein particles carried 95% of the cholesterol ester. Today in 2010, 30% of the population is obese, triglyceride levels are higher, HDL-C levels are lower, and LDL-P may carry as little as 60% of the circulating cholesterol ester. Applicants with cardiometabolic risk have an atherogenic dyslipidemia, which is characterized by a normal LDL-C, numerous small LDL-particles, mildly elevated triglycerides, and a depressed level of HDL--and a markedly increased risk of coronary artery disease. New and alternative lipid tests are available to help insurers better underwrite this new risk.
Related Concept Videos
Atherosclerosis I: Introduction
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Lipids: Dietary Sources and Requirements
Coronary Artery Disease I: Introduction